Qiagen N.V. (QGEN) Stock Price, Quote & News

Company Profile

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 31 77 355 6600

Website: www.qiagen.com

Address:

Hulsterweg 82, Venlo, Netherlands

Rage_Against_The_Machine Jun. 19 at 3:39 PM

Kalorama's latest IVD report spotlights $QGEN alongside Roche and Abbott as key players driving infectious disease testing innovation. With new products targeting STIs and sepsis, Qiagen's digital PCR tech could capitalize on the $12B molecular diagnostics market. That 108x trailing P/E still needs some heavy lifting though. https://www.prnewswire.com/news-releases/infectious-disease-testing-market-remains-dynamic-amid-post-pandemic-shifts-and-new-innovations-302485467.html

0 · Reply

swingingtech Jun. 19 at 2:14 PM

$QGEN https://wallstreetwaves.com/potential-stock-surge-for-qiagen-following-new-qiacuity-dpcr-ivd-partnership-with-gencurix/

0 · Reply

ZacksResearch Jun. 17 at 4:35 PM

$INCY surges 5.1% on global partnership news Incyte partners with $QGEN to develop a diagnostic panel for its MPN treatments, strengthening its precision medicine strategy. Year to date, INCY is up 3.1% vs. industry’s 0.9% decline. Discover how this deal might impact INCY's growth 👉 https://www.zacks.com/commentary/2507024/incyte-stock-rises-on-qiagen-deal-to-advance-blood-cancer-diagnostics?cid=sm-stocktwits-2-2507024-body&ADID=SYND_STOCKTWITS_TWEET_2_2507024_BODY

0 · Reply

ZacksResearch Jun. 16 at 1:16 PM

$QGEN partners with $INCY — a game-changer for onco-hematology diagnostics? 🤔 ⚕️ New collab to develop NGS panels for blood cancer gene detection 📊 QGEN's earnings yield of 5% vs. industry’s -29.4% is impressive 🚀 Shares up 4.7% over the past year against the industry’s 12.7% decline Discover how this could boost QGEN's market sentiment 👉 https://www.zacks.com/commentary/2503105/qgen-stock-rises-in-after-market-following-partnership-with-incyte?cid=sm-stocktwits-2-2503105-body&ADID=SYND_STOCKTWITS_TWEET_2_2503105_BODY

0 · Reply

ZacksResearch Jun. 16 at 11:58 AM

$QGEN pops after hours on new Incyte partnership — here's why it matters 👀 The two are teaming up to develop NGS-based companion diagnostics targeting blood cancers — a high-value, high-growth niche. Full details on the partnership here 👉 https://www.zacks.com/stock/news/2503105/qgen-stock-rises-in-after-market-following-partnership-with-incyte?cid=sm-stocktwits-2-2503105-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2503105_TEASER

0 · Reply

StocktwitsNews Jun. 16 at 4:07 AM

Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism $INCY $QGEN https://stocktwits.com/news/equity/markets/retail-investors-flock-to-incyte-as-drug-data-qiagen-deal-fuel-optimism/chlnXq1RRbv

0 · Reply

DonCorleone77 Jun. 16 at 12:37 AM

$QGEN $INCY $ILMN Qiagen, Incyte announce collaboration to develop companion diagnostics QIAGEN (QGEN) and Incyte (INCY) announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms, a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin, which is being developed in myelofibrosis and essential thrombocythemia. Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions.

0 · Reply

ZacksResearch Jun. 13 at 5:45 PM

$QGEN outpaces the industry, but can it keep up the momentum? 📈 With a Zacks Rank #2 and a 8.9% gain in the past year against a 13.3% industry decline, QIAGEN is thriving on strategic R&D investments, partnerships, and solid solvency. Yet, macroeconomic headwinds and fierce competition could pose challenges. Opportunity assessment here 👉 https://www.zacks.com/commentary/2498546/should-you-add-qiagen-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2498546-body&ADID=SYND_STOCKTWITS_TWEET_2_2498546_BODY

0 · Reply

ZacksResearch Jun. 13 at 4:22 PM

$QGEN holding steady through headwinds — but is it enough? Test menu expansion, key partnerships, and solid solvency are helping QGEN stay resilient in a tough macro environment. Fundamental insights here 👉 https://www.zacks.com/stock/news/2498546/should-you-add-qiagen-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2498546-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2498546_TEASER

0 · Reply

ZacksResearch Jun. 3 at 1:19 PM

$QGEN strengthens its position in oncology diagnostics with new partnerships! 🔬 🧬 Collaborations with Tracer Biotechnologies and Foresight Diagnostics set to advance MRD testing. 📉 Despite a slight stock dip, QIAGEN's strategic moves aim to bolster its market position. Discover why this could boost market sentiment for QGEN 👉 https://www.zacks.com/commentary/2482253/qgen-stock-to-gain-from-expanding-oncology-portfolio-via-new-alliances?cid=sm-stocktwits-2-2482253-body&ADID=SYND_STOCKTWITS_TWEET_2_2482253_BODY

0 · Reply

Qiagen and Gencurix Enter Clinical Diagnostics Partnership

Jun 18, 2025, 4:05 PM EDT - 7 days ago

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership

Jun 15, 2025, 4:00 AM EDT - 11 days ago

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

INCY

Jun 5, 2025, 6:20 PM EDT - 20 days ago

Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors

Jun 2, 2025, 2:05 PM EDT - 23 days ago

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships

Jun 2, 2025, 1:00 PM EDT - 23 days ago

Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma

May 22, 2025, 4:05 PM EDT - 4 weeks ago

QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

May 15, 2025, 7:30 AM EDT - 5 weeks ago

Qiagen Beats Earnings, But Its Expensive Valuation Caps Upside Potential

May 12, 2025, 4:05 PM EDT - 6 weeks ago

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software

May 8, 2025, 2:48 PM EDT - 6 weeks ago

Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:20 PM EDT - 7 weeks ago

QIAGEN announces plans for transition in leadership of Supervisory Board

May 7, 2025, 4:05 PM EDT - 7 weeks ago

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

May 7, 2025, 8:45 AM EDT - 7 weeks ago

QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting

May 3, 2025, 10:47 AM EDT - 7 weeks ago

Activist Fivespan has a stake in Qiagen. Here are 3 levers to boost the company's growth and improve value

Apr 29, 2025, 4:05 PM EDT - 2 months ago

QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control

Apr 22, 2025, 4:05 PM EDT - 2 months ago

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025

Apr 15, 2025, 1:30 AM EDT - 2 months ago

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation

Apr 8, 2025, 11:22 AM EDT - 2 months ago

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

Apr 6, 2025, 2:28 PM EDT - 2 months ago

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

Apr 1, 2025, 1:30 AM EDT - 3 months ago

QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

Mar 31, 2025, 6:00 AM EDT - 3 months ago

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

Mar 6, 2025, 1:00 AM EST - 4 months ago

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

Mar 3, 2025, 1:00 AM EST - 4 months ago

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing

Feb 25, 2025, 4:39 PM EST - 4 months ago

Qiagen N.V.: Some Clarity Needed Before Buying The Dip

Feb 13, 2025, 4:05 PM EST - 4 months ago

QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region

Feb 6, 2025, 4:49 PM EST - 4 months ago

Qiagen N.V. (QGEN) Q4 2024 Earnings Call Transcript

Feb 5, 2025, 4:05 PM EST - 5 months ago

QIAGEN delivers solid Q4 2024 growth ahead of outlook

Feb 4, 2025, 4:05 PM EST - 5 months ago

QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent

Jan 16, 2025, 4:05 PM EST - 5 months ago

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million

Jan 15, 2025, 8:13 AM EST - 5 months ago

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

Jan 12, 2025, 1:05 PM EST - 5 months ago

QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase

Jan 10, 2025, 1:30 AM EST - 5 months ago

QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples

Jan 9, 2025, 4:05 PM EST - 5 months ago

QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care

Jan 7, 2025, 4:05 PM EST - 6 months ago

QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content

Dec 12, 2024, 4:05 PM EST - 6 months ago

QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data

Dec 5, 2024, 4:05 PM EST - 7 months ago

QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation

Nov 28, 2024, 6:00 AM EST - 7 months ago

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing

Nov 27, 2024, 4:05 PM EST - 7 months ago

QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis

Nov 7, 2024, 3:58 PM EST - 8 months ago

Qiagen N.V. (QGEN) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:35 PM EST - 8 months ago

Diagnostics firm Qiagen reports rise in third-quarter revenue

Nov 4, 2024, 1:30 AM EST - 8 months ago

QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

Oct 29, 2024, 2:30 AM EDT - 8 months ago

QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment

Oct 10, 2024, 4:05 PM EDT - 9 months ago

QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications

Oct 10, 2024, 7:41 AM EDT - 9 months ago

QIAGEN N.V. to release results for Q3 2024 and hold webcast

Oct 7, 2024, 4:05 PM EDT - 9 months ago

Global TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killer

Sep 30, 2024, 4:05 PM EDT - 9 months ago

QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology

Sep 26, 2024, 4:05 PM EDT - 9 months ago

QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays

Sep 25, 2024, 4:05 PM EDT - 9 months ago

PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples

Sep 23, 2024, 4:05 PM EDT - 9 months ago

QIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy database

Sep 18, 2024, 4:05 PM EDT - 10 months ago

QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform

Rage_Against_The_Machine Jun. 19 at 3:39 PM

0 · Reply

swingingtech Jun. 19 at 2:14 PM

$QGEN https://wallstreetwaves.com/potential-stock-surge-for-qiagen-following-new-qiacuity-dpcr-ivd-partnership-with-gencurix/

0 · Reply

ZacksResearch Jun. 17 at 4:35 PM

0 · Reply

ZacksResearch Jun. 16 at 1:16 PM

0 · Reply

ZacksResearch Jun. 16 at 11:58 AM

0 · Reply

StocktwitsNews Jun. 16 at 4:07 AM

0 · Reply

DonCorleone77 Jun. 16 at 12:37 AM

0 · Reply

ZacksResearch Jun. 13 at 5:45 PM

0 · Reply

ZacksResearch Jun. 13 at 4:22 PM

0 · Reply

ZacksResearch Jun. 3 at 1:19 PM

0 · Reply

ZacksResearch Jun. 3 at 11:10 AM

$QGEN quietly building a moat in oncology? New MRD testing alliances are expanding its portfolio and reinforcing its push into personalized cancer care — a long-term growth lever. Full breakdown here 👉 https://www.zacks.com/stock/news/2482253/qgen-stock-to-gain-from-expanding-oncology-portfolio-via-new-alliances?cid=sm-stocktwits-2-2482253-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2482253_TEASER

0 · Reply

Thestocktraderhubzee Jun. 2 at 5:03 PM

$QGEN Foresight Diagnostics Partners With QIAGEN To Develop, Commercialize Kit-Based Version Of CLARITY Assay For Lymphoma

0 · Reply

ZacksResearch May. 23 at 1:13 PM

$QGEN teams up with ID Solutions to boost QIAcuity's reach in oncology dPCR assays, aiming to strengthen its cancer research leadership. Read the full story here: https://www.zacks.com/stock/news/2476645/qgen-stock-might-gain-following-new-partnership-with-id-solutions?cid=sm-stocktwits-2-2476645-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2476645_TEASER

0 · Reply

DonCorleone77 May. 22 at 8:15 PM

$QGEN Qiagen expands digital PCR oncology research portfolio QIAGEN "announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR assays and customized molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications. The combination of QIAGEN's global reach and automation expertise with the assay development and manufacturing capabilities of ID Solutions will strengthen QIAGEN's position in oncology research. Under the agreement, ID Solutions will manufacture and supply dPCR assays for non-clinical research use on QIAGEN's QIAcuity platforms. These assays are optimized to simultaneously detect multiple mutations in cell-free DNA from plasma and genomic DNA from formalin-fixed, paraffin-embedded tissue. QIAGEN will commercialize these kits starting in Europe as the first region, with the potential for future expansion into other regions."

0 · Reply

Estimize May. 14 at 8:03 PM

Wall St is expecting 0.60 EPS for $QGEN Q2 [Reporting 08/12 AMC] http://www.estimize.com/intro/qgen?chart=historical&metric_name=eps&utm_co

0 · Reply

ZacksResearch May. 13 at 11:10 AM

$QGEN inks an agreement to acquire Genoox for $70 million in cash. The acquisition expands QIAGEN's QDI portfolio. Discover more: https://www.zacks.com/stock/news/2467669/qiagen-stock-gains-following-the-acquisition-of-genoox?cid=sm-stocktwits-2-2467669-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2467669_TEASER

0 · Reply

Armonica423 May. 10 at 10:04 PM

$QGEN Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

0 · Reply

DonCorleone77 May. 7 at 8:53 PM

$QGEN Qiagen reports Q1 adjusted EPS 55c, consensus 51c Reports Q1 revenue $483M, consensus $476.78M. "QIAGEN delivered a solid start to 2025, exceeding our outlook on both sales and adjusted earnings. Our growth pillars QIAstat-Dx and QuantiFERON both posted double-digit sales gains, while QIAcuity and QIAGEN Digital Insights both continued to build momentum and in Sample technologies we are focusing on automation and preparing for new instrument launches. These advancements highlight the execution of our focused strategy and our ability to perform amid global uncertainty. We have reaffirmed our full-year 2025 targets and remain committed to delivering solid, profitable growth as a foundation for achieving our 2028 ambitions," said Thierry Bernard, CEO of QIAGEN.

0 · Reply

1986iamwallstreet May. 7 at 8:23 PM

$QGEN Qiagen Q1 Adj. EPS $0.55 Misses $0.56 Estimate, Sales $483.00M Miss $507.25M Estimate

1 · Reply

Thestocktraderhubzee Apr. 30 at 10:41 AM

WATCHLIST APR 30 2025. $GH Guardant Health Presents Data From Study Showing That Methylation-Based Shield MCD Test Showed High Specificity And Clinically Meaningful Sensitivity Across Ten Tumor Types $QGEN QIAGEN Expands Digital PCR Portfolio With New Lentivirus Solutions To Strengthen Cell And Gene Therapy Quality Control $ENVX B. Riley Securities Maintains Buy on Enovix, Lowers Price Target to $12 $ABVX Abivax Completes Enrollment For Phase 3 ABTECT Trials In Patients With Moderately To Severely Active Ulcerative Colitis $LEG Leggett & Platt shares are trading higher Tuesday. The company on Monday reported better-than-expected Q1 EPS results and raised its FY25 EPS guidance.

0 · Reply

JarvisFlow Apr. 21 at 1:01 PM

Baird has updated their rating for Qiagen ( $QGEN ) to Neutral with a price target of 43.

0 · Reply

Estimize Apr. 17 at 11:06 AM

Wall St is expecting 0.50 EPS for $QGEN Q1 [Reporting 05/07 AMC] http://www.estimize.com/intro/qgen?chart=historical&metric_name=eps&utm_co

0 · Reply

Market Cap	10.50B
Revenue (ttm)	1.98B
Net Income (ttm)	83.59M
EPS (ttm)	N/A
PE Ratio	20.20
Forward PE	19.95
Profit Margin	4.23%
Debt to Equity Ratio	0.41

Volume	1,897,600
Avg Vol	1,426,322
Day's Range	N/A - N/A
Shares Out	222.29M
Stochastic %K	86%
Beta	0.67
Analysts	Strong Sell
Price Target	$49.41